CXCR4 and neoplasm: Administered activity of [177Lu]Lu-/[90Y]Y-PentixaTher or drug doses of “cold” CXCR4 antagonists could then be increased in patients with high tumor burden, maximizing efficacy in sites of disease and reducing off-target effects in unaffected organs.